



# NORDIC AML GROUP

## Azacitidine-Venetoclax - recent clinical updates

The NAMLG's Educational Working Group is hosting a webinar on **September 24, 2024, from 15:00 to 16:30 CEST**. The webinar will provide the latest insights on using Aza-Ven in AML treatment including discussions from a Nordic perspective. Topics will include its application as a first-line treatment, dosing optimizations, and strategies for maintenance therapy.

When 2024-09-24, 15:00 - 16:30 CEST

How Via Zoom, using [this link](#) and the following passcode: **82KpouDe**

Program	15:00 - 15:05	Welcome (A. Österroos, Uppsala University Hospital, Uppsala, chair of EWG)
	15:05 - 15:20	<b>Aza-Ven as first-line treatment before allo-SCT</b> (Dr. K. Pratz, Hospital of the University of Pennsylvania, Philadelphia)
	15:20 - 15:30	Discussion and questions
	15:30 - 15:35	<b>Case presentations</b> (EWG members)
	15:35 - 15:55	<b>Dosing optimisation(s) of Aza-Ven - when, who and how?</b> (Dr. A-L. Tølbøll Sørensen, Rigshospitalet, Copenhagen)
	15:55 - 16:15	<b>Maintenance therapy with Aza-Ven</b> (Dr. M. Jädersten, Karolinska Institute, Stockholm)
	16:15 - 16:25	Discussion and questions
	16:25 - 16:30	Closing remarks

---

The webinar is supported by

abbvie

&



The KG Jebsen Centre for  
Mveloid Blood Cancer